The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.